absoluteantibody/Ab00188-10.3 Anti-IL-2R alpha (CD25) [Basiliximab]/Ab00188-10.3/ 200 µg

Description:RecombinantmonoclonalantibodytoIL-2Ralpha(CD25).ManufacturedusingAbAb’sRecombinantPlatformwithvariableregions(i.e.specificity)fromthetherapeuticantibodyBasiliximab.ThisantibodywascreatedusingourproprietaryFcSilent™engineeredFcdomaincontainingkeypointmutationsthatabrogatebindingtoFcgammareceptors.
SpeciesandIsotype:HumanIgG1,FcSilent™,kappa
CloneNumber:Basiliximab
UniProtAccessionNumberofTargetProtein:P01589
AlternativeName(s)ofTarget:Interleukin-2receptorsubunitalpha;IL-2receptorsubunitalpha;IL-2Rsubunitalpha;IL-2-RA;IL2-RA;TACantigen;p55;CD25.
PublishedApplication(s):FC;Block;IF;IHC;WB
PublishedSpeciesReactivity:Human;RhesusMonkey;CynomolgusMonkey
Immunogen:BasiliximabwaspreparedbyimmunizingBALB/cmicewithCTC16cells.
Specificity:BasiliximabrecognisesthehumanIL-2Randbindstotheepitope(116)ERIYHFV(122)withintheextracellulardomainoftheCD25subunit–bindingisabolishedwhen2ormoreresidueswithintheepitopearemutated.ThisepitopeoverlapswiththeinteractionsiteofCD25andIL-2.CD25isfoundinthehigh-affinityIL-2R(αβγc)–TcellsonlyexpressCD25uponactivation.IL-2bindingtoIL-2RonTcellsmodulatesproliferationanddifferentiation.
ApplicationNotes:Basiliximabisderivedfromthemurineanti-Tacantibody.Fortheclinicallyusedformat,thevariableregionsfromthisantibodyweregraftedontothesequenceofthehumanIgG1κconstantregions.BasiliximabbindingtoCD25competitivelyblockstheinteractionofIL-2RwithitsligandIL-2onthesurfaceofTcells.BlockingthisinteractionpreventsTcellreplicationandTcell-mediatedBcellactivation.Basiliximabbindingsuppressestheimmunesysteminhibitsthepathwayactivatingthecellularimmuneresponsetoallograftrejection.IL-2signallingsuppressioncanadditionallypreventacutegraft-versus-hostdisease,autoimmunedisordersandmalignanciessuchasTcellleukemias(Binderetal,2007).BasiliximabhasalsobeenusedinFC,IF,IHCandWBstudies,whichenablesthedetectionofCD25.
AntibodyFirstPublishedin:
Kovariketal.Dispositionofbasiliximab,aninterleukin-2receptormonoclonalantibody,inrecipientsofmismatchedcadaverrenalallografts.Transplantation.1997Dec27;64(12):1701-5.PMID:9422405Noteonpublication:Describesthecharacterizationofthepharmacokineticsofthetherapeuticantibody.

ProductForm

Purification:ProteinAaffinitypurified
StorageRecommendation:Storeat4°Cforupto3months.Forlongertermstoragealiquotintosmallvolumesandstoreat-20°C
Concentration:Seeviallabel.